OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantActivity from announced rounds
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
Draig Therapeutics develops neuropsychiatric medicines.
Develops precision immunoregulatory medicines based on tissue Treg biology
Provides healthcare financing and payments solutions
Alchemab Therapeutics develops antibody medicines by studying people resilient to disease.